Milestone Pharmaceuticals (NASDAQ:MIST) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research note published on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $5.00 price objective on the stock.

Other equities research analysts have also issued reports about the stock. TD Cowen lowered shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 1st. TD Securities lowered shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st. Finally, Cowen lowered shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $7.00.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST opened at $1.73 on Thursday. The company’s fifty day moving average price is $1.18 and its 200 day moving average price is $1.69. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $2.75. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The firm has a market capitalization of $92.49 million, a P/E ratio of -2.14 and a beta of 0.92.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.12). As a group, sell-side analysts predict that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MIST. Jones Financial Companies Lllp increased its stake in Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares during the period. XTX Topco Ltd increased its stake in Milestone Pharmaceuticals by 52.7% in the first quarter. XTX Topco Ltd now owns 52,004 shares of the company’s stock valued at $42,000 after purchasing an additional 17,950 shares during the period. National Bank of Canada FI increased its stake in Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after purchasing an additional 11,600 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Milestone Pharmaceuticals in the fourth quarter valued at $73,000. Finally, Walleye Capital LLC acquired a new position in Milestone Pharmaceuticals in the first quarter valued at $74,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.